HIVMA welcomes the release of the comprehensive National HIV/AIDS Strategy Federal Implementation Plan that provides an important road map for reducing new HIV infections by 90% by 2030.
HIVMA welcomes the release of the comprehensive National HIV/AIDS Strategy Federal Implementation Plan that provides an important road map for reducing new HIV infections by 90% by 2030.
IDSA and HIVMA are immensely grateful for Dr. Anthony Fauci’s contributions to the identification, treatment and containment of infectious diseases through his 38 years of leadership of the National Institute of Allergy and Infectious Diseases.
IDSA and HIVMA say that while barriers to ending the HIV epidemic are significant, the goal could be within reach with broad-based policy reforms at the federal, state and local levels.
IDSA applauds new legislation introduced by Rep. Sean Patrick Maloney (D-NY) to ensure monkeypox testing is available at no cost to the public.
IDSA and HIVMA support the Biden Administration’s decision to declare the monkeypox outbreak a public health emergency.
As monkeypox cases top more than 5,800 across 48 states, there is no time to waste.
Today’s U.S. Department of Health and Human Services announcement that nearly 800,000 additional doses of the monkeypox vaccine are now available for distribution is a welcome development, but much more is urgently needed.
IDSA and HIVMA appreciate the CDC’s swift action in responding to health care provider concerns regarding the significant procedural barriers required to obtain tecovirimat, or TPOXX, through the Expanded Access for Investigational New Drug program.
HIVMA is encouraged that funding for key HIV programs has increased in the U.S. House of Representatives Appropriations Committee’s funding bill for Labor, Health and Human Services programs for fiscal year 2023.
Increasing access to monkeypox testing and expanding vaccination against infection to people at high risk are needed and welcome steps in efforts to control spread and minimize symptoms.
IDSA and HIVMA condemn the U.S. Supreme Court decision overturning Roe v. Wade that sanctions government interference in patient autonomy and care and threatens the sanctity of the provider-patient relationship.
People who may be most in need of antiviral treatment for COVID-19 may not be receiving it because of where they live, according to a recent report from the U.S. Centers for Disease Control and Prevention.